MyoKardia Revenue and Competitors
Estimated Revenue & Valuation
- MyoKardia's estimated annual revenue is currently $33.6M per year.
- MyoKardia received $Undisclosed in venture funding in August 2017.
- MyoKardia's estimated revenue per employee is $745,733
- MyoKardia's total funding is $98M.
Employee Data
- MyoKardia has 45 Employees.
- MyoKardia grew their employee count by -10% last year.
MyoKardia's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP - Market Access | Reveal Email/Phone |
2 | VP, Portfolio Strategy and Alliance Management | Reveal Email/Phone |
3 | Senior Medical Director, Clinical Science | Reveal Email/Phone |
4 | Clinical Trial Leader | Reveal Email/Phone |
5 | Senior Scientist | Reveal Email/Phone |
6 | Scientist I | Reveal Email/Phone |
MyoKardia Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is MyoKardia?
Our Mission: Change the world for patients with cardiovascular disease through bold and innovative science. MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Our initial focus: treatment of heritable cardiomyopathies, a group of genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. We are a growing community of employees who enjoy working with and learning from each other. We collaborate in a way that ensures the growth of the company as well each employee individually. MyoKardia is committed to creating a culture that's centered on our core values. We seek individuals who not only offer expertise in their respective fields, but can serve as cultural leaders and role models for our values. Apply: http://myokardia.com/careersOpp.php Learn More: http://myokardia.com/
keywords:Biotechnology,Healthcare,Pharmaceuticals
$98M
Total Funding
45
Number of Employees
$33.6M
Revenue (est)
-10%
Employee Growth %
N/A
Valuation
N/A
Accelerator
MyoKardia News
Before MyoKardia, Giankakos held leadership roles at MAP Pharmaceuticals, Codexis, Inc. and Madygen.
Maraganore was Alnylam's founding CEO and just left the company last year, while Gianakakos served as MyoKardia CEO for eight years until the...
Bristol Myers Squibb paid $13bn for mavacamten's developer, Myokardia, so it needs the project to be a hit. Today the company got a boost...
MyoKardia to Evaluate Mavacamten as an Alternative to Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Patients.
Durability of Mavacamten's Safety and Efficacy Profile Demonstrated through Nine Months in this Study of Patients with Symptomatic, ...
Other Companies in South San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.1M | 46 | -32% | N/A |
#2 | $7.1M | 46 | 2% | N/A |
#3 | $3.6M | 46 | 35% | $120M |
#4 | $9M | 46 | 31% | N/A |
#5 | $10.2M | 47 | -4% | N/A |
MyoKardia Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2012-09-21 | $38.0M | A | Article | |
| 2015-05-01 | $46.0M | B | Article | |
| 2017-08-09 | $Undisclosed | Undisclosed | J.P. Morgan Securities LLC | Article |